Last reviewed · How we verify
NCT07122856
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients
trial in Alzheimer Disease in 100 participants. Not yet recruiting.
15 March 2026
Quick facts
| Lead sponsor | Centre Hospitalier de Gonesse |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 September 2025 |
| Primary completion | 15 March 2026 |
| Estimated completion | 15 March 2026 |
| Sites | 1 location across France |
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Mini-Mental State Examination — all drugs for Mini-Mental State Examination →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
- Neuropsychological Tests — all drugs for Neuropsychological Tests →
Sponsor
Centre Hospitalier de Gonesse
Who can join
Eligibility, any sex, with Alzheimer Disease or Mini-Mental State Examination. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12 months. Researchers will review medical records from patients seen at the Memory Clinic of Gonesse Hospital and analyze information such as age, education, medical history, nutrition, mood, and caregiver burden. The goal is to better understand what influences early cognitive performance and how quickly it changes, to help improve patient care and planning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07122856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Centre Hospitalier de Gonesse trials
Trials by the same sponsor.
- NCT07172542 — High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers · not yet recruiting
- NCT07064265 — Assessment of Interprofessional Competencies of Healthcare Professionals Before and After Healthcare Simulation Sessions · not yet recruiting
- NCT07122869 — Eligibility of Patients Referred to Emergency Departments by Their General Practitioners for Care in Walk-in Clinics: A · recruiting
- NCT07030036 — Screening for Cognitive Disorders in Multiple Sclerosis · not yet recruiting
- NCT06994026 — Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07122856 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Gonesse
- Last refreshed: 14 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07122856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing